Montreal (Quebec)– Clemex Technologies Inc. (“Clemex” or the “Company”) (TSXV: CXG.A) today announced that its Board of Directors has received a non-binding letter of intent from RAL Diagnostics SAS, Zwick Roell AG and Mr. Yves Bassat (collectively, the “Principal Shareholders”) confirming their intention to acquire all of the issued and outstanding Class A common shares of Clemex, other than shares held directly or indirectly by them, at a price of $0.20 in cash per share, representing total consideration of approximately $3.8 million. The $0.20 per share cash consideration represents a premium of 100% to the last trading price of the Shares on the TSX Venture Exchange on July 21, 2016 (the last date upon which the Shares traded) and a premium of approximately 66.7% to the highest trading price of the Shares on the TSX Venture Exchange since January 1, 2016.

Mr. Bassat is the President and Chief Executive Officer of Clemex. RAL Diagnostics SAS and Zwick Roell AG together own, di